Roerholt C et al. – Anti-osteoporotic prescription rates were found to be low, especially following hip fracture. However, persistence has improved with almost 2/3 of patients who began raloxifene or weekly alendronate obtaining treatment durations equalling those of the licensing trials. Methods
Aim was to assess the initiation and compliance with anti-osteoporotic therapy in 152,777 fracture pts in a national population-based cohort study
National registers were used to identify pts born 1945 or earlier who sustained a fracture 1997–2004
Initiation of anti-osteoporotic therapy was defined as redemption of at least one prescription in the year following fracture
Persistence was defined as duration of time maintaining a medication possession ratio >75%
Results
Treatment initiation within 1 year was highest after spine fracture
Following hip fracture, 9.2% of women and 4.1% of men began therapy in 2004 vs 3.4% and 0.7% in 1997, respectively
Median persistence (yrs) was 2.8 for daily alendronate, 3.8 for weekly alendronate, 2.5 for etidronate and 4.7 for raloxifene
The risk of discontinuing or changing therapy increased with age
See all
